Permeon reveals discovery of Intraphilins as new approach to intracellular biologic drugs
Permeon Biologics, a biopharmaceutical company pioneering a novel class of intracellular protein biologics, today announced the discovery of an entirely new class of naturally occurring human supercharged proteins called Intraphilins. The sequence and structure of these naturally supercharged human proteins enable biologic drugs to penetrate and function inside of mammalian cells. This new class of proteins is the foundation of Permeon Biologics' novel Intraphilin Technology Platform and provides an innovative approach to develop intracellular protein biologic drugs, such as intracellular monoclonal antibodies and enzyme replacement therapies. Intraphilins enable functional proteins to act inside cells to treat disease, impacting over 1,500 intracellular target proteins currently considered undruggable with available technologies.